Portfolio Streamlining At GSK India But Long Term Commitment Intact
GlaxoSmithKline has initiated portfolio rationalization measures in India as the British multinational reshapes its emerging markets business model with an eye on driving sustained profitable growth. But the company has also underscored its long-term commitment to the country, where it expects to build on its “strong heritage” and expand patient access.
You may also be interested in...
GlaxoSmithKline has identified five core therapy areas including dermatology, gastrointestinals and the respiratory segment for a focused effort to accelerate growth on the competitive Indian market. Segments like central nervous system (CNS) and the government institutional business could potentially be defocused.
GlaxoSmithKline is believed to be keen to divest close to a dozen tail-end brands across therapy groups including anti-infectives and dermatology in India as it tweaks its portfolio to focus on sustained profitable growth.
Novel asthma/COPD drugs, including GlaxoSmithKline’s biologic therapy Nucala, are on the horizon in India, set to expand treatment options in the competitive segment. But pricing is expected to be key in pushing uptake, and health care delivery in asthma/COPD in India remains rather sub-optimal, notwithstanding the interest around new launches.